These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19947374)

  • 1. [Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer].
    Kaprin AD; Gafanov PA; Fastovets SV
    Vopr Onkol; 2009; 55(4):474-6. PubMed ID: 19947374
    [No Abstract]   [Full Text] [Related]  

  • 2. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
    Koutsilieris M; Dimopoulos T; Milathianakis C; Bogdanos J; Karamanolakis D; Pissimissis N; Halapas A; Lembessis P; Papaioannou A; Sourla A
    BJU Int; 2007 Jul; 100 Suppl 2():60-2. PubMed ID: 17594363
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal treatment for progression.
    Miller K
    Eur J Cancer; 2009 Sep; 45 Suppl 1():158-60. PubMed ID: 19775614
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma.
    Vainas G; Pasaitou V; Galaktidou G; Maris K; Christodoulou K; Constantinidis C; Kortsaris AH
    J Exp Clin Cancer Res; 1997 Mar; 16(1):119-26. PubMed ID: 9148872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel chemotherapies in development for management of castration-resistant prostate cancer.
    Tewari AK; George DJ
    Curr Opin Urol; 2013 May; 23(3):220-9. PubMed ID: 23511791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The benefits of early androgen blockade.
    Maroni PD; Crawford ED
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
    Klotz L; Schellhammer P; Carroll K
    BJU Int; 2004 Jun; 93(9):1177-82. PubMed ID: 15180600
    [No Abstract]   [Full Text] [Related]  

  • 14. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
    Matveev BP; Bukharkin BV
    Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
    Erten C; Karaca B; Kucukzeybek Y; Gorumlu G; Cengiz E; Gul MK; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
    BJU Int; 2009 Jul; 104(1):107-14. PubMed ID: 19191785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine therapy for prostate cancer.
    Damber JE
    Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete response after treatment with a somatostatin analogue in an adult patient with recurrent medulloblastoma.
    Glas M; Hennemann B; Hirschmann B; Marienhagen J; Schmidt-Wolf I; Herrlinger U; Bogdahn U; Hau P
    Acta Oncol; 2008; 47(3):479-80. PubMed ID: 17934891
    [No Abstract]   [Full Text] [Related]  

  • 19. Current treatment of advanced prostate cancer.
    Ismail M; Gomella LG
    Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
    Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
    Anticancer Res; 2005; 25(5):3597-9. PubMed ID: 16101186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.